2022
Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
Ryman J, Weaver J, Hu T, Weinberger D, Yee K, Sachs J. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. Npj Vaccines 2022, 7: 140. PMID: 36344529, PMCID: PMC9640717, DOI: 10.1038/s41541-022-00538-1.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineSerotype-specific IgG concentrationsInvasive pneumococcal diseaseVaccine effectivenessIgG concentrationsPneumococcal diseaseImmune responseAntibody concentrationsProtective antibody concentrationsNext-generation vaccinesPCV13 recipientsConjugate vaccineImmunogenicity dataPCV7PCV13SerotypesVaccineDiseasePlaceboImmunogenicityRecipients
2021
Real-time monitoring of the rollout of pneumococcal conjugate vaccines in rural India using a digital tracking platform
Nagar R, Ambiya M, Dalal S, Bhadauriya P, Abdullah H, Shahnawaz M, Weinberger D. Real-time monitoring of the rollout of pneumococcal conjugate vaccines in rural India using a digital tracking platform. Gates Open Research 2021, 5: 16. DOI: 10.12688/gatesopenres.13206.1.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineBooster doseConjugate vaccineImmunization programsRoutine immunization programPercent of childrenMonths of ageFirst doseThird doseVaccination statusPrimary dosesSecond dosePneumococcal transmissionVaccine programDigital health platformPCV13Vaccine deliveryOnly dosesDoseMaximal benefitVaccineTime pointsRural IndiaDosesHealth platform